Andrew Huberman

Huberman rejects universal founder-performance protocols: the practical constraint is an honest assessment of sleep need, energy, and recovery in the current season of work. He feels great on seven hours, groggy on eight, functional on six, and “cratered” after two nights of zero-to-four hours; copying Elon Musk’s presumed four-to-five-hour requirement is “ridiculous.” From zero to maybe the first four years of a company, the realistic protocol may simply be: “Get as much done as you can, and don’t impair yourself with an injury or chronic disease.”

Sleep is the near-term neurotechnology wedge because users already accept physiological measurement there and the productivity payoff is immediate. Huberman reduces rapid downshifting to three requirements: leave planning for pure sensation, lower heart rate with long exhales, and blur awareness of limb position through rocking or eye movements. He tested an eye mask that reportedly measures REM directly, induces sleep-promoting eye movements through stimulation behind the ears, and amplifies REM; he expects related technology in roughly seven to 12 months and says, “I wish I had a stake in this company. I don’t.”

The health-optimization media market is approaching a credibility reset after attention incentives pushed educators toward theatrical escalation. Huberman calls the discourse “a fucking disaster,” argues that “it’s very easy to get attention” but “very hard to keep respect,” and expects consumers to abandon burdensome daily rituals. His forecast is a downturn in optimization content—particularly “low-level noise” around 2027-28—followed by trained PhDs, MDs, and pharmacologists building a more serious category.

Huberman’s largest strategic prediction is that Meta, OpenAI, Anthropic, and Elon’s Neuralink effort will converge on biotech centered on reading from and writing to the nervous system. The core technical prize is non-invasive, spatially and temporally precise control that can activate, quiet, or grade specific brain regions, with AI learning the dose appropriate to each person. “That’s what the real arms race of AI is about,” not merely better LLMs.

Commercial adoption may progress from wearables to direct autonomic sensing, minimally invasive stimulators, and eventually genetically addressable neural circuits. Huberman predicts that within 12 months perhaps “20% of the entrepreneurial world” will at least consider a vagal stimulator if implantation feels no more invasive than a piercing. Longer term, he imagines a viral vector installing neural channels that a light- or ultrasound-emitting hat could control, with AI titration and safeguards such as a required pill creating an “AND gate.”

The largest scientific constraint is not hardware but the absence of a reliable model linking neural activity to memory and thought. In experiments Huberman highlights, reactivating the neurons associated with a learned behavior produced that behavior even when the cells were stimulated in reverse order or simultaneously—challenging the textbook assumption that temporal sequence carries the memory. Because the same neurons participate in many perceptions and behaviors, precision targeting could still create unanticipated effects: “We don’t really understand what a thought is.”

Huberman argues that genetic enhancement is no longer a hypothetical governance problem, but carefully separates established events from speculation. He points to He Jiankui’s CRISPR-edited twins, embryo screening, and follistatin gene-therapy efforts as evidence that human genetic-control technologies already exist, while repeatedly saying he does not know whether reported experiments continue or whether He is operating in Austin. His stance is “more excited than concerned” only if the work is openly discussed, carefully governed, and equipped with real safeguards.

The foundational opportunity is to define waking brain states as precisely as sleep stages, then match each state to the work it serves. Huberman believes this is “totally doable,” but his closing career lesson is equally relevant to research and company-building: “Success is determined by how precisely you match your genuine curiosity to the work that you do.” Sustained advantage comes from pursuing the question one genuinely needs answered, not imitating whichever field or protocol currently attracts capital and attention.